Publication: Randomized controlled trial of subconjunctival bevacizumab injection in impending recurrent pterygium: A pilot study
Issued Date
2012-02-01
Resource Type
ISSN
15364798
02773740
02773740
Other identifier(s)
2-s2.0-84855825280
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Cornea. Vol.31, No.2 (2012), 155-161
Suggested Citation
Kaevalin Lekhanont, Thanikan Patarakittam, Prakairut Thongphiew, Olan Suwan-Apichon, Prut Hanutsaha Randomized controlled trial of subconjunctival bevacizumab injection in impending recurrent pterygium: A pilot study. Cornea. Vol.31, No.2 (2012), 155-161. doi:10.1097/ICO.0b013e3182151e0e Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/15001
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Randomized controlled trial of subconjunctival bevacizumab injection in impending recurrent pterygium: A pilot study
Other Contributor(s)
Abstract
PURPOSE: To investigate the efficacy and safety of subconjunctival bevacizumab injection for the treatment of impending recurrent pterygium. METHODS: A prospective, randomized, single-masked, controlled trial was conducted in 80 patients with impending recurrent pterygium. Patients were randomized into 4 groups using random tables: 20 patients served as a control and treatment groups received a single intralesional injection of 1.25 mg (20 patients, group 1), 2.5 mg (20 patients, group 2), or 3.75 mg (20 patients, group 3) of bevacizumab. Topical 0.1% fluorometholone and ocular lubricant were administered 4 times daily for 1 month in all groups. Severity of impending recurrent pterygium graded by photographic assessment (at baseline, 3 days, 1 week, and 2, 4, 8, and 12 weeks after treatment) and true recurrence were the main outcome measures. RESULTS: At 3 days, the conjunctival injection significantly decreased in all treatment groups (P < 0.01). A significant decrease in the conjunctival injection was still observed until 2 and 4 weeks in only groups 2 and 3, respectively (P < 0.05). The conjunctival hyperemia appeared to increase back to baseline at later time points. No significant difference in the mean severity score among the groups was observed. True recurrence was found in 62 patients with no statistically significant difference among the groups. No serious ocular or systemic adverse events were seen. CONCLUSIONS: A single subconjunctival bevacizumab injection seems to only partially and transiently decrease conjunctival vascularization in impending recurrent pterygium in a dose-dependent manner. This treatment does not cause regression or reduce the recurrent rate of impending recurrent pterygium. Copyright © 2012 by Lippincott Williams & Wilkins.